Abstract #0220

Evaluation of neuroinflammation in Alzheimer’s disease on human subjects using third-generation TSPO ligand [18F]-GE180

Zhengshi Yang¹, Karthik Sreenivasan¹, Xiaowei Zhuang¹, Aaron Ritter¹, Jessica Caldwell¹, Sarah J Banks², Virendra Mishra¹, Marwan Sabbagh¹, Dietmar Cordes^1,3, and Jeffrey Cummings^1,4

¹Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, United States, ²Department of Neuroscience, University of California, San Diego, CA, United States, ³Department of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States, ⁴Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV, United States

Inflammatory reactions contribute to disease progression and severity of Alzheimer’s disease (AD). While multiple animal studies have suggested that increased neuroinflammation occurs in AD, few studies have investigated neuroinflammation in human subjects. This is the first study using the third-generation TSPO ligand [18F]-GE180 to evaluate the neuroinflammation in AD on human subjects. Our study suggests that neuroinflammation accumulates together with amyloid deposition and reaches a plateau when the regional amyloid SUVR reaches 1.1 threshold. Compared to amyloid pathology, neuroinflammation is more closely related to hyperconnectivity in MCI/AD subjects.

This abstract and the presentation materials are available to members only; a login is required.

Join Here